Glaukos Announces Participation in Baird Healthcare Conference

LAGUNA HILLS, Calif.–(BUSINESS WIRE)– Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology
company focused on the development and commercialization of breakthrough
products and procedures designed to transform the treatment of glaucoma,
today announced that its management is scheduled to participate in the
Robert W. Baird Global Healthcare Conference on Wednesday, September 7,
2016, at 3:10 p.m. EDT in New York City.

A live audio webcast for this event will be available in the Investors
section of the Glaukos website at http://investors.glaukos.com
and will be archived for 90 days.

About Glaukos

Glaukos (www.glaukos.com)
is an ophthalmic medical technology company focused on the development
and commercialization of breakthrough products and procedures designed
to transform the treatment of glaucoma, one of the world’s leading
causes of blindness. The company pioneered Micro-Invasive Glaucoma
Surgery, or MIGS, to revolutionize the traditional glaucoma treatment
and management paradigm. Glaukos launched the iStent^®,
its first MIGS device, in the United States in July 2012 and is
leveraging its platform technology to build a comprehensive and
proprietary portfolio of micro-scale injectable therapies designed to
address the complete range of glaucoma disease states and progression.
The company believes the iStent, measuring 1.0 mm long and 0.33
mm wide, is the smallest medical device ever approved by the FDA.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160824006119/en/